SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global human microbiome market is valued at US$ 46.9 billion in 2017, and is projected to exhibit a CAGR of 17.5% over the forecast period (2018 – 2026).
Key Trends and Analysis of the Global Human Microbiome Market:
Key trends in market are High number of collaboration activities between various player, introduction of probiotics, and increasing prevalence of disease such as Clostridium Infection, Cancer, and Others.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/182
Growing collaboration activities between various players in industry and between different players and research institutes is expected to boost the expansion and development of novel medicines for variety of diseases. For instance, Enterome Bioscience SA and Takeda Pharmaceutical Company Ltd entered into partnership in 2016 for a drug discovery of potential new therapeutics in gastrointestinal disorders by utilizing microbiome targets as approach. It is evident that such efforts are accelerating the research and development of microbiome platform.
Growing incidence of Clostridium difficile infection and other disease conditions in which human microbiome product is used. According to data given by Centre for Disease Control and Prevention in October 2017, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the China and Hong Kong, affecting around 36.1 cases/100,000 person in 2014, an annual increase of 26%. It puts According to study published in Clinical Infectious Disease journal in 2015, approximately 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI.
The new microciome diagnostics and therapeutics is new concept which creates concern about safety over micro-biome based products. There is concern about even true efficacy of microbiome based platform. The establishment of link between dysbiosis of microbiome and disease is critical to establish clinical potential. For a microbiome-based diagnostic, establishing clinical evidence of the link between biomarkers and disease (e.g. - Cancer biomarkers) states would be significant. This scenario presents inadequate regulatory framework for microbiome based diagnostic and drugs and a challenge for designing clinical trials which may affect clinical trial outcomes and reproducibility.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182
Key Market Takeaways:
- The human microbiome market is expected to exhibit a CAGR of 17.5% during the forecast period (2018 – 2026), attributed to increasing prevalence of cardiovascular cancer. According to International Agency for Research on Cancer September 2018 estimates, around 9.6 million death and 18.1 million new cases of cancer will be diagnosed in 2018
- Introduction of probiotic may induce change in intestinal microbiota and can stabilize microbial communities, which may prevent gut inflammation, propelling growth of the human microbiome market over the forecast period. For instance, in May 2015, Biofodan A/S introduced it FastMelt Immuno at Vitafoods in Geneva. FastMelt Immuno contains probiotic strain and excipients in powder form.
- Key players operating in the global human microbiome market include, Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
